Patents by Inventor Zaifang REN

Zaifang REN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SSAO inhibitors and use thereof
    Patent number: 11964942
    Abstract: The application relates to a compound of Formula (I?) or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I?) or (I), and a method of treating or preventing a disease in which SSAO plays a role.
    Type: Grant
    Filed: May 5, 2022
    Date of Patent: April 23, 2024
    Assignee: Eccogene (Shanghai) Co., Ltd.
    Inventors: Zaifang Ren, Xuefeng Sun, Qing Xu
  • Substituted imidazoles as GLP-1 receptor agonists
    Patent number: 11584751
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of GLP-1 receptor, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which GLP-1 receptor plays a role.
    Type: Grant
    Filed: November 2, 2021
    Date of Patent: February 21, 2023
    Assignee: Eccogene (Shanghai) Co., Ltd.
    Inventors: Zaifang Ren, Xuefeng Sun, Jingye Zhou, Qing Xu
  • TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME
    Publication number: 20230051320
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of GLP-1 receptor, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which GLP-1 receptor plays a role.
    Type: Application
    Filed: July 20, 2021
    Publication date: February 16, 2023
    Inventors: Zaifang REN, Xuefeng SUN, Jingye ZHOU, Qing XU
  • SSAO INHIBITORS AND USE THEREOF
    Publication number: 20230026801
    Abstract: The application relates to a compound of Formula (I?) or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I?) or (I), and a method of treating or preventing a disease in which SSAO plays a role.
    Type: Application
    Filed: May 5, 2022
    Publication date: January 26, 2023
    Inventors: Zaifang REN, Xuefeng SUN, Qing XU
  • PHENYL-[1,3]DIOXOLO[4,5-C]PYRIDINYL-PHENYL-, PHENYL-[1,3]DIOXOLO[4,5-C]PYRIDINYL-HETEROARYL-, OR PHENYL-(1,3)DIOXO[4,5-C]PYRIDINYL-PIPERIDINYL-METHYL-OXETANYLMETHYL-1H-BENZO[D]IMIDAZOLE-CARBOXYLIC ACID DERIVATIVES AND METHODS OF USING SAME
    Publication number: 20220348564
    Abstract: The application relates to a compound of Formula (Y) or Formula (A): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of GLP-1 receptor, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which GLP-1 receptor plays a role.
    Type: Application
    Filed: March 24, 2022
    Publication date: November 3, 2022
    Inventors: Zaifang REN, Xuefeng SUN, Jingye ZHOU
  • SSAO inhibitors and use thereof
    Patent number: 11472769
    Abstract: The application relates to a compound of Formula (I?) or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I?) or (I), and a method of treating or preventing a disease in which SSAO plays a role.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: October 18, 2022
    Assignee: Eccogene (Shanghai) Co., Ltd.
    Inventors: Zaifang Ren, Xuefeng Sun, Qing Xu
  • Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor
    Patent number: 11286248
    Abstract: Disclosed are a compound as shown in formula (I), and an isomer thereof or a pharmaceutically acceptable salt thereof, and involved is the use thereof in the preparation of drugs for treating FGFR-associated diseases.
    Type: Grant
    Filed: February 2, 2019
    Date of Patent: March 29, 2022
    Assignee: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD.
    Inventors: Yang Zhang, Zhifei Fu, Miaorong Luo, Zaifang Ren, Dongjie Hu, Jie Li, Jian Li, Shuhui Chen
  • SSAO INHIBITORS AND USE THEREOF
    Publication number: 20210147360
    Abstract: The application relates to a compound of Formula (I?) or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I?) or (I), and a method of treating or preventing a disease in which SSAO plays a role.
    Type: Application
    Filed: October 28, 2020
    Publication date: May 20, 2021
    Inventors: Zaifang REN, Xuefeng SUN, Qing XU
  • PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR
    Publication number: 20210040070
    Abstract: Disclosed are a compound as shown in formula (I), and an isomer thereof or a pharmaceutically acceptable salt thereof, and involved is the use thereof in the preparation of drugs for treating FGFR-associated diseases.
    Type: Application
    Filed: February 2, 2019
    Publication date: February 11, 2021
    Applicant: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD.
    Inventors: Yang ZHANG, Zhifei FU, Miaorong LUO, Zaifang REN, Dongjie HU, Jie LI, Jian LI, Shuhui CHEN